| 10/7/2021 |
Todos and NLC Pharma report positive clinical data for Covid-19 test |
medicaldevice-network.com |
Todos and NLC Pharma report positive clinical data for Covid-19 test] Todos and NLC Pharma report positive clinical data for Covid-19 test A steady inverse link between ct value and 3CL protease activity was found in hospitalised and non-hospitalised Covid-19 subjects. Todos Medical and its joint venture partner NLC Pharma have reported positive clinical validation data from a study where the former’s SARS-CoV-2 ... |
| 10/7/2021 |
Malaysia buys 150,000 courses of Merck's COVID-19 pill |
wxerfm.com |
... would be the first oral antiviral medication for COVID-19 if it gets regulatory approval, could halve the chances of dying or being hospitalised for those most at risk of contracting severe COVID-19, clinical data has shown. The data sparked large demand for the drug in Asia, with South Korea, Singapore and Australia announcing similar deals to buy the Merck pill this week. Taiwan and Thailand are also in ... |
| 10/7/2021 |
US FDA grants 510(k) clearance for BD Rotarex System expanded indications |
medicaldevice-network.com |
Todos and NLC Pharma report positive clinical data for Covid-19 test] US FDA grants 510(k) clearance for BD Rotarex System expanded indications The Rotarex Atherectomy System now has expanded indications for treatment inside peripheral arteries. The US Food and Drug Administration (FDA) has granted 510(k) clearance for Becton, Dickinson and Company’s (BD) Rotarex Atherectomy System expanded indications. A rotational excisional device, the Rotarex Atherectomy System is ... |
| 10/7/2021 |
Malaysia buys 150,000 courses of Merck's COVID-19 pill |
dukefmduluth.com |
... would be the first oral antiviral medication for COVID-19 if it gets regulatory approval, could halve the chances of dying or being hospitalised for those most at risk of contracting severe COVID-19, clinical data has shown. The data sparked large demand for the drug in Asia, with South Korea, Singapore and Australia announcing similar deals to buy the Merck pill this week. Taiwan and Thailand are also in ... |
| 10/7/2021 |
COVID-19 vaccine linked to reduction in US senior deaths, HHS says |
fox26houston.com |
WASHINGTON - With more than 83% of U.S. adults aged 65 and older vaccinated against the novel coronavirus, a new study suggests vaccines have reduced COVID-19 infections and deaths in seniors.According to the study published by the Department of Health and Human Services, the purpose of the research was to identify associations between COVID-19 infections, hospitalizations and deaths among Medicare fee-for-service (FFS) beneficiaries and the proportion ... |
| 10/7/2021 |
Malaysia buys 150,000 courses of Merck's COVID-19 pill |
hot96.com |
... would be the first oral antiviral medication for COVID-19 if it gets regulatory approval, could halve the chances of dying or being hospitalised for those most at risk of contracting severe COVID-19, clinical data has shown. The data sparked large demand for the drug in Asia, with South Korea, Singapore and Australia announcing similar deals to buy the Merck pill this week. Taiwan and Thailand are also in ... |
| 10/7/2021 |
Malaysia buys 150,000 courses of Merck's COVID-19 pill |
q106fm.com |
... would be the first oral antiviral medication for COVID-19 if it gets regulatory approval, could halve the chances of dying or being hospitalised for those most at risk of contracting severe COVID-19, clinical data has shown.The data sparked large demand for the drug in Asia, with South Korea, Singapore and Australia announcing similar deals to buy the Merck pill this week. Taiwan and Thailand are also in ... |
| 10/7/2021 |
COVID-19 vaccine linked to reduction in US senior deaths, HHS says |
fox6now.com |
WASHINGTON - With more than 83% of U.S. adults aged 65 and older vaccinated against the novel coronavirus, a new study suggests vaccines have reduced COVID-19 infections and deaths in seniors.According to the study published by the Department of Health and Human Services, the purpose of the research was to identify associations between COVID-19 infections, hospitalizations and deaths among Medicare fee-for-service (FFS) beneficiaries and the proportion ... |
| 10/7/2021 |
Merck's molnupiravir will be a blockbuster drug during pandemic. What about endemic COVID-19? | FiercePharma |
FiercePharma |
... Ronny Gal estimates.Gal used the influenza market as the benchmark for his calculation and incorporated efficacy data from molnupiravir and COVID-19 vaccines. He now projects Merck—as the only company with positive clinical data —will take half of the endemic oral drug market, with Pfizer and Roche potentially sharing the rest if their contenders prove successful.Molnupiravir’s 50% reduction in hospitalization and death risk came from the ... |
| 10/7/2021 |
Denali makes ALS play, hustling Sanofi-partnered drug into phase 2 and sharing early data on internal program |
FierceBiotech |
... of DNL343, it will also start the process of answering outstanding questions about how patients respond to the molecule.“Primary pushback from investors is: hard to know what we have until there is more clinical data , biology around ALS is extremely challenging, preclinical models are not well predictive,” analysts at Jefferies wrote in a note to investors. The analysts expect Denali to eventually land a big partnership to fund ... |
| 10/7/2021 |
Malaysia buys 150,000 courses of Merck's COVID-19 pill |
froggyweb.com |
... would be the first oral antiviral medication for COVID-19 if it gets regulatory approval, could halve the chances of dying or being hospitalised for those most at risk of contracting severe COVID-19, clinical data has shown. The data sparked large demand for the drug in Asia, with South Korea, Singapore and Australia announcing similar deals to buy the Merck pill this week. Taiwan and Thailand are also in ... |
| 10/7/2021 |
Malaysia buys 150,000 courses of Merck's COVID-19 pill |
kelofm.com |
... would be the first oral antiviral medication for COVID-19 if it gets regulatory approval, could halve the chances of dying or being hospitalised for those most at risk of contracting severe COVID-19, clinical data has shown. The data sparked large demand for the drug in Asia, with South Korea, Singapore and Australia announcing similar deals to buy the Merck pill this week. Taiwan and Thailand are also in ... |
| 10/7/2021 |
Malaysia buys 150,000 courses of Merck's COVID-19 pill |
krro.com |
... would be the first oral antiviral medication for COVID-19 if it gets regulatory approval, could halve the chances of dying or being hospitalised for those most at risk of contracting severe COVID-19, clinical data has shown. The data sparked large demand for the drug in Asia, with South Korea, Singapore and Australia announcing similar deals to buy the Merck pill this week. Taiwan and Thailand are also in ... |
| 10/7/2021 |
Zacks Investment Research Downgrades Matinas BioPharma (NYSEAMERICAN:MTNB) to Hold - Transcript Daily |
transcriptdaily.com |
... Äôs lead anti-fungal product candidate, MAT2203, utilizes its proprietary lipid nano-crystal formulation technology for the safe and effective delivery of the broad-spectrum fungicidal agent, amphotericin B. Based on the positive patient clinical data reported in 2017, Matinas is preparing for a potential Phase 2 pivotal trial of MAT2203 for prevention of invasive fungal infections in patients with acute lymphoblastic leukemia. ‚ÄúGet Matinas BioPharma alerts: Separately, HC ... |
| 10/7/2021 |
Zacks Investment Research Downgrades Matinas BioPharma (NYSEAMERICAN:MTNB) to Hold - Stock Observer |
thestockobserver.com |
... Äôs lead anti-fungal product candidate, MAT2203, utilizes its proprietary lipid nano-crystal formulation technology for the safe and effective delivery of the broad-spectrum fungicidal agent, amphotericin B. Based on the positive patient clinical data reported in 2017, Matinas is preparing for a potential Phase 2 pivotal trial of MAT2203 for prevention of invasive fungal infections in patients with acute lymphoblastic leukemia. ‚ÄúGet Matinas BioPharma alerts: Separately, HC ... |
| 10/7/2021 |
Malaysia buys 150,000 courses of Merck's COVID-19 pill - The Jerusalem Post |
jpost.com |
... would be the first oral antiviral medication for COVID-19 if it gets regulatory approval, could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, clinical data has shown. The data sparked large demand for the drug in Asia, with South Korea, Singapore, and Australia announcing similar deals to buy the Merck pill this week. Taiwan and Thailand are also in ... |
| 10/7/2021 |
Malaysia buys 150,000 courses of Merck's COVID-19 pill |
Yahoo News |
... would be the first oral antiviral medication for COVID-19 if it gets regulatory approval, could halve the chances of dying or being hospitalised for those most at risk of contracting severe COVID-19, clinical data has shown.The data sparked large demand for the drug in Asia, with South Korea, Singapore and Australia announcing similar deals to buy the Merck pill this week. Taiwan and Thailand are also in ... |
| 10/7/2021 |
Malaysia buys 150,000 courses of Merck's COVID-19 pill |
my957.com |
... would be the first oral antiviral medication for COVID-19 if it gets regulatory approval, could halve the chances of dying or being hospitalised for those most at risk of contracting severe COVID-19, clinical data has shown. The data sparked large demand for the drug in Asia, with South Korea, Singapore and Australia announcing similar deals to buy the Merck pill this week. Taiwan and Thailand are also in ... |
| 10/7/2021 |
Malaysia buys 150,000 courses of Merck's COVID-19 pill |
wimz.com |
... would be the first oral antiviral medication for COVID-19 if it gets regulatory approval, could halve the chances of dying or being hospitalised for those most at risk of contracting severe COVID-19, clinical data has shown. The data sparked large demand for the drug in Asia, with South Korea, Singapore and Australia announcing similar deals to buy the Merck pill this week. Taiwan and Thailand are also in ... |
| 10/7/2021 |
Malaysia buys 150,000 courses of Merck's COVID-19 pill |
whtc.com |
... would be the first oral antiviral medication for COVID-19 if it gets regulatory approval, could halve the chances of dying or being hospitalised for those most at risk of contracting severe COVID-19, clinical data has shown. The data sparked large demand for the drug in Asia, with South Korea, Singapore and Australia announcing similar deals to buy the Merck pill this week. Taiwan and Thailand are also in ... |